Home/Pipeline/DE-127

DE-127

Dry Eye Disease

Phase 1Active

Key Facts

Indication

Dry Eye Disease

Phase

Phase 1

Status

Active

Company

Santen Pharmaceutical

About Santen Pharmaceutical

Santen Pharmaceutical is a leading global player in the ophthalmology market, dedicated to addressing unmet medical needs in eye diseases. The company leverages its deep expertise in ocular drug delivery and formulation to build a diversified portfolio spanning glaucoma, retinal diseases, dry eye, and inflammation. With a long history of innovation and a commitment to research, Santen aims to contribute to the well-being of patients worldwide through its specialized ophthalmic solutions.

View full company profile

Therapeutic Areas

Ophthalmology Glaucoma Retinal Diseases Dry Eye Disease Ocular Inflammation Ocular Allergy

Other Dry Eye Disease Drugs

Drug	Company	Phase	Status
CEQUA (cyclosporine)	Sun Pharmaceutical	Approved	Commercial
DE-120 (Ciclosporin ophthalmic gel)	Rohto Pharmaceutical	Phase 3	Active
DE-130 (Eicosapentaenoic Acid Ethyl Ester)	Santen Pharmaceutical	Phase 3	Active
DE-126 (SIP Receptor Modulator)	Santen Pharmaceutical	Phase 2	Active
OTX-CSI (cyclosporine insert)	Ocular Therapeutix	Phase 3	Completed (Did not meet primary endpoint)
voclosporin	Aurinia Pharmaceuticals	Phase 2/3	Discontinued (Nov 2023)
HROW-324 (SHP-659)	Harrow Health	Phase 2	Active
PL9643 (Melody-1)	Palatin Technologies	Phase 3	Active